Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Syndax Announces PDUFA Action Date Extension for Revumenib NDA in KMT2Ar Acute Leukemia
Details : SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of adult and pediatric patients with relapsed/refractory KMT2A-rearranged (KMT2Ar) acute leukemia.
Brand Name : SNDX-5613
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 29, 2024
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Revumenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Syndax to Advance Revumenib into Phase 1b Trial for Metastatic MSS CRC
Details : SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of Relapsed/Refractory metastatic microsatellite stable (MSS) colorectal cancer.
Brand Name : SNDX-5613
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 06, 2024
Lead Product(s) : Revumenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Syndax Completes Enrollment in AUGMENT-101 Trial of Relapsed/Refractory AML
Details : SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of Relapsed/Refractory mNPM1 Acute Myeloid Leukemia.
Brand Name : SNDX-5613
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 28, 2024
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Syndax Announces FDA Priority Review of NDA for Revumenib in R/R Acute Leukemia
Details : SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of adult and pediatric patients with relapsed or refractory KMT2A-rearranged acute leukemia.
Brand Name : SNDX-5613
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 26, 2024
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Revumenib,Venetoclax,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SNDX-5613 (revumenib) is a highly selective, oral menin inhibitor which is under phase 1 clinical development for the treatment of patients with Acute Leukemias.
Brand Name : SNDX-5613
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2023
Lead Product(s) : Revumenib,Venetoclax,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Revumenib is a potent, selective, small molecule inhibitor of the menin-KMT2A binding interaction that is being developed for the treatment of KMT2A-rearranged, also known as mixed lineage leukemia rearranged or MLLr, acute leukemias including ALL and AM...
Brand Name : SNDX-5613
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2023
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SNDX-5613 (revumenib) is an investigational, novel, orally available Menin-MLL1 inhibitor, which is investigated for the treatment of R/R KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL).
Brand Name : SNDX-5613
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 02, 2023
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SNDX-5613 (revumenib) is an investigational, novel, orally available Menin-MLL1 inhibitor, which is investigated for the treatment of relapsed/refractory KMT2Ar acute leukemia.
Brand Name : SNDX-5613
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 29, 2023
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Goldman Sachs & Co.
Deal Size : $172.5 million
Deal Type : Public Offering
Details : SNDX-5613 (revumenib) is an investigational, novel, orally available Menin-MLL1 inhibitor. The interaction of Menin and MLL1 has been demonstrated to play an essential role in the leukemic transformation for acute leukemia patients with MLLr or NPM1 muta...
Brand Name : SNDX-5613
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 14, 2022
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Goldman Sachs & Co.
Deal Size : $172.5 million
Deal Type : Public Offering
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SNDX-5613 (revumenib) is an investigational, novel, orally available Menin-MLL1 inhibitor.2 The interaction of Menin and MLL1 has been demonstrated to play an essential role in the leukemic transformation for acute leukemia patients with MLLr or NPM1 mut...
Brand Name : SNDX-5613
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2022
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?